Thursday, September 23, 2021
HomeNewsAbbott Receives FDA Clearance For its Artificial Intelligence Imaging Technology

Abbott Receives FDA Clearance For its Artificial Intelligence Imaging Technology

Abbott uses optical coherence tomography technology coupled with its own artificial intelligence Ultreon software to accurately detect calcium deposition and diameter of blood vessels to aid doctors treat cardiac patients.

American healthcare company Abbott receives clearance from the Food and Drug Administration (FDA) for its artificial intelligence imaging technology. The company’s technology is capable of recognizing comprehensive blood flow in coronary arteries and blockages using its optical coherence tomography (OCT) solution. 

The platform is powered by Abbott’s in-house developed software named Ultreon. This platform will significantly help doctors to make accurate decisions while diagnosing and treating patients suffering from several heart diseases. 

Abbott had received the CE Mark approval in Europe earlier this year. With this new clearance, the firm is now set to widely deploy artificial intelligence tools in the healthcare industry to assist physicians at a larger scale. 

Read More: Intel Launches AI for Workforce Program in the United States

Director of the DeMatteis Cardiovascular Institute at St. Francis Hospital and Heart Center in New York, Ziad Ali, said, “Abbott’s new Ultreon Software for OCT provides an automated, comprehensive view of the artery that facilitates physician decision-making. Ultreon Software guides stents to be placed with precision. These types of innovative technologies are instrumental in providing the best care for our patients.” 

The company unveiled its artificial intelligence software at the EuroPCR 2021 event held in France. The software quickly received approval from the Japanese government after the event. 

According to research conducted by Abbott, more than 83% of surveyed physicians believed that new technologies like optical coherence tomography could help improve the quality of treatment for cardiac patients. 

Managing Director and Chief Medical Officer at Abbott’s vascular business said, “As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care.” 

He also mentioned that artificial intelligence enables the company’s software Ultreon to automatically detect calcium deposition and blood vessel diameter, which helps doctors use stents at precisely calculated locations. 

Subscribe to our newsletter

Subscribe and never miss out on such trending AI-related articles.

We will never sell your data

Join our Telegram and WhatsApp group to be a part of an engaging community.

Dipayan Mitra
Dipayan is a news savvy writer, who does not leave a single page of news paper unturned. He is also a professional vocalist who enjoys ghazals. Building a dog shelter is his forever dream.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular